Company intelligence / Profile preview

CereHealth

Denver, Colorado, United Statescerescan.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s flagship product, CereMetrix®, has received FDA 510(k) clearance. It provides advanced quantitative brain SPECT analysis with population templates for improved diagnostic accuracy. The platforms are used by radiologists and clinicians to enhance neurodiagnostic evaluations through objective voxel-level perfusion measurement and automated reporting. No drug or therapeutic clinical trial results apply.

Therapeutic areas: Neurology
Modalities: DeviceSoftware platform (Medical Analytics as a Service)
Industry: Medical Imaging

Partnerships

Contract research organizations (CROs) for clinical trials workflow integration; specific partners not named

Beyond the preview

Go deeper on CereHealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CereHealth.

Explore the full profile